Expanded Access for Treatment With Imetelstat
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Geron Corporation
- Registration Number
- NCT05937568
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 51
- Registration Number
- NCT05371964
- Locations
- 🇺🇸
Texas Oncology, Tyler, Texas, United States
🇺🇸City of Hope, Irvine, California, United States
🇺🇸University of Miami, Coral Gables, Florida, United States
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
- Conditions
- Myelofibrosis
- Interventions
- Drug: Best Available Therapy (BAT)
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 320
- Registration Number
- NCT04576156
- Locations
- 🇮🇹
AOU Federico II, Napoli, Italy
🇮🇹Ospedale Civile S.Maria delle Croci, AUSL Ravenna, Ravenna, Italy
🇮🇹Arcispedale S Maria Nuova, AO di Reggio Emilia, Reggio Calabria, Italy
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 289
- Registration Number
- NCT02598661
- Locations
- 🇹🇷
Ege Universitesi Tip Fakultesi - Hematology, İzmir, Turkey
🇳🇱Meander Medisch Centrum, Amersfoort, Netherlands
🇳🇱VU Medisch Centrum, Amsterdam, Netherlands
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 107
- Registration Number
- NCT02426086
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
- Conditions
- Myeloid MalignanciesPrimary MyelofibrosisSecondary Myelofibrosis
- Interventions
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 80
- Registration Number
- NCT01731951
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
- Conditions
- Locally Recurrent or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 166
- Registration Number
- NCT01256762
- Locations
- 🇺🇸
Clearview Cancer Center, Huntsville, Alabama, United States
🇺🇸Medical Oncology Hematology, Waterbury, Connecticut, United States
🇺🇸Mid Illinois Hematology & Oncology, Normal, Illinois, United States
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT01243073
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸MDACC - Orlando, Orlando, Florida, United States
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 13
- Registration Number
- NCT01242930
- Locations
- 🇺🇸
University of Maryland Medical Center - M & S Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Sidney Kimmel Cancer Center Johns Hopkins Hospital, Baltimore, Maryland, United States
Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 116
- Registration Number
- NCT01137968
- Locations
- 🇺🇸
Integrated Community Oncology Network, Jacksonville, Florida, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States